CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 57 enrolled
Drug / intervention
Methyl B12 +1 moredrug
Likely dose
Methyl B12 75 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01039792
NCT01039792Phase 3Completed
CompareCT.gov

Double Blind Placebo Controlled Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism

University of California, San Francisco·interventional·Posted Dec 25, 2009·Updated Feb 24, 2017

In Brief

A Phase 3 clinical trial evaluating Methyl B12 and Placebo for Autistic Disorder. Completed, enrolled 57 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether the supplement Methyl B12 is effective in treating some of the symptoms of Autism.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutistic Disorder
CountriesUnited States
CollaboratorsUniversity of California, Davis, Arkansas Children's Hospital Research Institute

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 25, 2009
Enrollment StartJan 1, 2010
Primary CompletionOct 1, 2013
Study CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 16.5 years ago

Interventions

Methyl B12drug

75 µg/Kg subcutaneously injected once every 3 days

Placebodietary

placebo